"At Yale New Haven Health, we deliver extraordinary, compassionate care by working alongside providers and payers on innovative, cost-effective healthcare delivery models that improve care and value for patients - and enhance the health of our communities."

During the past decade, Smilow Cancer Center/Yale-New Haven Hospital conducted 194 clinical trials. In the 10-year time frame, 194 clinical trials started and 70 clinical trials were completed, i.e. on average, 36.1% percent of trials that started reached the finish line to date. In the past 5 years, 55 clinical trials started and 57 clinical trials were completed. i.e. 103.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Smilow Cancer Center/Yale-New Haven Hospital" #1 sponsor was "National Cancer Institute (NCI)" with 61 trials, followed by "Yale University" with 25 trials sponsored, "Pfizer" with 22 trials sponsored, "SWOG Cancer Research Network" with 19 trials sponsored and "Alliance for Clinical Trials in Oncology" with 19 trials sponsored. Other sponsors include 79 different institutions and companies that sponsored additional 54 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Smilow Cancer Center/Yale-New Haven Hospital" #1 collaborator was "National Cancer Institute (NCI)" with 46 trials as a collaborator, "Merck Sharp & Dohme LLC" with 7 trials as a collaborator, "Genentech, Inc." with 6 trials as a collaborator, "Canadian Cancer Trials Group" with 4 trials as a collaborator and "NRG Oncology" with 4 trials as a collaborator. Other collaborators include 43 different institutions and companies that were collaborators in the rest 46 trials.

According to Clinical.Site data, the most researched conditions in "Smilow Cancer Center/Yale-New Haven Hospital" are "Breast Cancer" (10 trials), "Recurrent Squamous Cell Lung Carcinoma" (9 trials), "Stage IV Squamous Cell Lung Carcinoma AJCC v7" (8 trials), "Colorectal Cancer" (6 trials) and "Melanoma" (6 trials). Many other conditions were trialed in "Smilow Cancer Center/Yale-New Haven Hospital" in a lesser frequency.

Most popular intervention types in "Smilow Cancer Center/Yale-New Haven Hospital" are "Drug" (179 trials), "Other" (71 trials), "Biological" (60 trials), "Procedure" (39 trials) and "Radiation" (19 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (40 trials), "Computed Tomography" (22 trials), "Biospecimen Collection" (21 trials), "Pembrolizumab" (20 trials) and "Nivolumab" (17 trials). Other intervention names were less common.

The vast majority of trials in "Smilow Cancer Center/Yale-New Haven Hospital" are 189 trials for "All" genders, 25 trials for "Female" genders and 8 trials for "Male" genders.

Currently, there are NaN active trials in "Smilow Cancer Center/Yale-New Haven Hospital". undefined are not yet recruiting, 56 are recruiting, 79 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 53 completed trials in Smilow Cancer Center/Yale-New Haven Hospital, 4 suspended trials, and 24 terminated clinical trials to date.

Out of the total trials that were conducted in Smilow Cancer Center/Yale-New Haven Hospital, 57 "Phase 1" clinical trials were conducted, 116 "Phase 2" clinical trials and 64 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 8 trials that are defined as “Not Applicable".